We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Zoetis Inc | NYSE:ZTS | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.35 | 0.20% | 174.06 | 174.66 | 172.58 | 174.05 | 1,995,065 | 01:00:00 |
By Emon Reiser
Zoetis updated its full-year guidance with a lower range for its revenue and a higher range for its net income.
As it reported its second-quarter results for the period ended June 30, the veterinary-drug maker said its revenue for the full fiscal year is expected to be between $8.5 billion and $8.65 billion, down from its previous guidance $8.575 billion to $8.725 billion that it had expected in the first quarter.
Zoetis expects its 2023 net income to be between $2.4 billion and $2.46 billion, a higher range compared with its previous full-year guidance of between $2.345 billion and $2.4 billion.
Its full-year earnings per share are expected to be between $5.15 and $5.27 a share, up from its previous full-year guidance of between $5.03 and $5.14 a share.
Adjusted earnings are expected to be $5.37 to $5.47 a share, up from its previous full-year guidance of between $5.34 and $5.44 a share.
Zoetis reported sales and revenue above analysts estimates in the second quarter as its companion pet business grew.
Write to Emon Reiser at emon.reiser@wsj.com
(END) Dow Jones Newswires
August 08, 2023 08:05 ET (12:05 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Zoetis Chart |
1 Month Zoetis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions